5-Fluorouracil causes leukocytes attraction in the peritoneal cavity by activating autophagy and HMGB1 release in colon carcinoma cells

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages 1381-1389

  Cottone, Lucia ^a,b   Capobianco, Annalisa ^a   Gualteroni, Chiara ^a   Perrotta, Cristiana ^c   Bianchi, Marco E ^a,b   Rovere Querini, Patrizia ^a,b   Manfredi, Angelo A ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

5 Fluorouracil; Autophagy; Chemoattraction; HMGB1; Peritoneal carcinomatosis

Indexed keywords

FLUOROURACIL; HIGH MOBILITY GROUP B1 PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE MIGRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEAL CAVITY; PROTEIN SECRETION; ANIMAL; C57BL MOUSE; CELL MOTION; COLONIC NEOPLASMS; CYTOLOGY; DRUG EFFECTS; HUMAN; LEUKOCYTE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HMGB1 PROTEIN; HUMANS; LEUKOCYTES; MICE; MICE, INBRED C57BL; PERITONEAL CAVITY;

EID: 84922265802     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29125     Document Type: Article

References (42)

1. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7.
2. Erez N, Coussens LM. Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer 2011;128:2536-44.
3. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-22.
4. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
5. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
6. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
7. Sconocchia G, Zlobec I, Lugli A, et al. Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 2011;128:2663-72.
8. Bianchi ME, Manfredi AA. Immunology. Dangers in and out. Science 2009;323:1683-4.
9. Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012;12:860-75.
10. Kang R, Zhang Q, Zeh HJ, III. HMGB1 in cancer: good, bad, or both? Clin Cancer Res 2013;19:4046-57.
11. Yang J, Chen L, Ding J, et al. High mobility group box-1 induces migration of vascular smooth muscle cells via TLR4-dependent PI3K/Akt pathway activation. Mol Biol Rep 2012;39:3361-7.
12. Lolmede K, Campana L, Vezzoli M, et al. Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J Leukoc Biol 2009;85:779-87.
13. Riuzzi F, Sorci G, Donato R. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem 2006;281:8242-53.
14. Vezzoli M, Castellani P, Corna G, et al. HMGB1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal 2011;15:2161-74.
15. Bacci M, Capobianco A, Monno A, et al. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol 2009;175:547-56.
16. Robinson-Smith TM, Isaacsohn I, Mercer CA, et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 2007;67:5708-16.
17. Cottone L, Valtorta S, Capobianco A, et al. Evaluation of the role of tumor-associated macrophages in an experimental model of peritoneal carcinomatosis using (18)F-FDG PET. J Nucl Med 2011;52:1770-7.
18. Ceelen WP. Current management of peritoneal carcinomatosis from colorectal cancer. Minerva Chir 2013;68:77-86.
19. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
20. Li W, Wu K, Zhao E, et al. HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection. Biochem Biophys Res Commun 2013;436: 156-61.
21. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
22. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5.
23. Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 1987;262:16625-35.
24. Degryse B, Bonaldi T, Scaffidi P, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152:1197-206.
25. Rauvala H, Rouhiainen A. Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim Biophys Acta 2010;1799:164-70.
26. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-70.
27. Penzo M, Molteni R, Suda T, et al. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J Immunol 2010;184:4497-509.
28. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
29. Orlova VV, Choi EY, Xie C, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007;26:1129-39.
30. Chavakis E, Hain A, Vinci M, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007;100:204-12.
31. Campana L, Bosurgi L, Bianchi ME, et al. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol 2009;86:609-15.
32. Schiraldi M, Raucci A, Munoz LM, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012;209:551-63.
33. Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012;209:1519-28.
34. Venereau E, Schiraldi M, Uguccioni M, et al. HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol Immunol 2013;55:76-82.
35. Tang D, Kang R, Cheh CW, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010;29:5299-310.
36. Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012;488:670-4.
37. Lu B, Antoine DJ, Kwan K, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A 2014;111:3068-73.
38. Bianchi ME, Manfredi AA. How macrophages ring the inflammation alarm. Proc Natl Acad Sci U S A 2014;111:2866-7.
39. Liu L, Yang M, Kang R, et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011;25:23-31.
40. Tang D, Kang R, Livesey KM, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010;190:881-92.
41. Nars MS, Kaneno R. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer 2013;132:2471-8.
42. Bijnsdorp IV, Peters GJ, Temmink OH, et al. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer 2010;126:2457-68.